- Home
- FRA vs RGNX Comparison
FRA vs RGNX Comparison
Compare FRA & RGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FRA | RGNX |
|---|---|---|
| Founded | 2003 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 415.1M | 418.1M |
| IPO Year | N/A | 2015 |
Fundamental Metrics
Financial Performance| Metric | FRA | RGNX |
|---|---|---|
| Price | $10.59 | $7.71 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $28.75 |
| AVG Volume (30 Days) | 180.9K | ★ 804.5K |
| Earning Date | 01-01-0001 | 03-05-2026 |
| Dividend Yield | ★ 11.06% | N/A |
| EPS Growth | N/A | ★ 18.08 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $10,393,000.00 |
| Revenue This Year | N/A | $50.05 |
| Revenue Next Year | N/A | $23.31 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 126.48 |
| 52 Week Low | $10.57 | $5.04 |
| 52 Week High | $13.41 | $16.19 |
Technical Indicators
Market Signals| Indicator | FRA | RGNX |
|---|---|---|
| Relative Strength Index (RSI) | 25.77 | 38.89 |
| Support Level | N/A | N/A |
| Resistance Level | $13.05 | $9.28 |
| Average True Range (ATR) | 0.15 | 0.48 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 7.69 | 1.90 |
Price Performance
Historical ComparisonAbout FRA Blackrock Floating Rate Income Strategies Fund Inc
Blackrock Floating Rate Inc Stra Fd Inc is a United States-based diversified closed-ended management investment company. The Fund's investment objective is to provide shareholders with high current income and preservation of capital with investment in a diversified, leveraged portfolio consisting of floating-rate debt securities and instruments.
About RGNX REGENXBIO Inc.
Regenxbio Inc is a clinical-stage biotechnology company focused on the development of gene therapy treatments. Its product candidates are designed to deliver genes to cells to address genetic defects or enable the production of therapeutic proteins. The company is developing a pipeline of investigational gene therapy treatments using its NAV Technology Platform based on adeno-associated virus (AAV) vectors. Its internal research and development programs are focused on therapies for retinal, neuromuscular, and neurodegenerative diseases.